Opendata, web and dolomites

EIS SIGNED

An innovative, effective and minimally-invasive retinal cell therapy combined with a new injection system for treatment of retinal degenerative diseases.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EIS project word cloud

Explore the words cloud of the EIS project. It provides you a very rough idea of what is the project "EIS" about.

minimally    dosage    marrow    daily    initiated    office    drug    80    retina    everads    degenerative    first    clinical    billion    therapeutic    safe    hbm    suffering    optimal    plan    pigmentosa    cell    iop    vessels    rp    injection    amd    people    obtain    impairments    risk    longer    combination    geographic    ensures    utilizing    multiple    perform    macular    approximately    marketing    adult    chain    supply    performed    stromal    leaving    setting    intravitreal    fact    feasibility    platform    bone    ocular    degeneration    choroidal    causes    area    dr    mscs    techniques    pressure    device    standard    escalation    reduces    debilitating    subretinal    regard    patients    blood    mesenchymal    market    innovative    visual    ga    excellent    cells    cataract    trials    atrophy    age    million    glaucoma    severe    human    registered    opportunity    treatments    matrix    goto    consequence    organ    blindness    drafted    retinitis    life    treatment    injections    effect    innovation    treat    ivts    ivt    worldwide    retinal    photoreceptor    invasive    transplantation    disease    license    lasting    close    strategy    eis   

Project "EIS" data sheet

The following table provides information about the project.

Coordinator
EVERADS THERAPY LTD 

Organization address
address: 27 HABARZEL STREET MIGDALEI ORR BUILDING A 5TH FLO
city: TEL AVIV
postcode: n.a.
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    EVERADS THERAPY LTD IL (TEL AVIV) coordinator 50˙000.00

Map

 Project objective

Retinal degenerative disease is a debilitating condition with a major impact on daily life. This includes Geographic Atrophy(GA) - as a consequence of age-related macular degeneration (AMD) - and advanced Retinitis Pigmentosa (RP) - all characterized by photoreceptor loss. In fact, they are the main causes of registered blindness. In this regard, there are no currently effective treatments for patients suffering from GA a and RP, leaving approximately 2.6 million people across Europe and over 5 million worldwide with the risk of developing severe visual impairments. Standard techniques to treat GA and DR, including Intravitreal Injections (IVTs) and subretinal transplantation present major problems associated with them. Everads developed a treatment for macular and retinal degeneration, utilizing the innovative Everads Injection System (EIS), a minimally invasive platform for optimal injection of Adult Bone Marrow Mesenchymal Stromal Cells (hBM-MSCs). Unique treatment approach allows simple, office-based safe transplantation of hBM-MSCs in the matrix between the choroidal blood vessels, providing excellent distribution very close to the target organ (retina) and long-term therapeutic effects, targeting multi-billion market opportunity. The Everads treatment is safe, minimally-invasive, can be performed in an office setting and ensures 80% drug distribution in the retinal area, aiming for longer lasting effect of drug. It also reduces the risk of side effects like increased Intra Ocular Pressure (IOP), glaucoma, cataract typical of IVT injections. During the feasibility assessment, a goto market strategy and a supply chain will be established, and further development plan will be drafted. During the phase 2 of innovation project, Everads will perform further product development and cell distribution and dosage escalation activities. Multiple first in human clinical trials will be initiated to obtain marketing license as a drug-device combination product.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EIS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EIS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

PrasinoMed (2018)

First in the world ecological and sustainable cream for wound care, based on microalgaprasinococcus capsulatus

Read More  

In-Heal (2019)

Standardised administration device for raw medical herbs

Read More  

GREEN WHS (2019)

NATURE FRIENDLY WATER HYDRAULIC STEERING SYSTEM

Read More